Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3OP41)

Drug Name

LXR 623 Drug Info

Synonyms

LXR-623

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Oxysterols receptor LXR (NR1H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALX-101	DMCAFXM	Atopic dermatitis	EA80	Phase 2	[2]
RGX-104	DM5AIKR	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
BMS-779788	DMKR8S1	Arteriosclerosis	BD40	Phase 1	[1]
CS-8080	DMRH740	Arteriosclerosis	BD40	Phase 1	[1]
BMS-852927	DMZS1D2	Arteriosclerosis	BD40	Phase 1	[1]
XL-041	DMYSQHT	Arteriosclerosis	BD40	Phase 1	[4]
XL652/XL014	DM89NML	Cardiovascular disease	BA00-BE2Z	Phase 1	[5]
T0901317	DMZQVDI	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30.
5	Clinical pipeline report, company report or official report of Exelixis (2011).
6	The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003 Nov;44(11):2039-48.